Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide, affecting up to 25% of the general population. It is strongly associated with obesity, type 2 diabetes, and metabolic syndrome. The pathogenesis involves insulin resistance leading to fatty infiltration of the liver followed by oxidative stress causing inflammation and fibrosis. Clinical features are often asymptomatic, though elevated liver enzymes and hepatomegaly may be seen. Diagnosis relies on excluding other causes of liver disease and imaging or biopsy. Potential therapies focus on lifestyle changes like diet, exercise and weight loss as well as treatments targeting underlying conditions and antioxidants.
NAFLD is a vast topic and recently gaining a lot of importance. Fatty liver, NASH, are other topics discussed here. sleissenger, sheila sherlock and Harrisons are used for reference
NAFLD is a vast topic and recently gaining a lot of importance. Fatty liver, NASH, are other topics discussed here. sleissenger, sheila sherlock and Harrisons are used for reference
One of the common liver problems, fatty liver is a condition in which the liver cells are accumulated with fats. Though, not life-threatening, in some cases, it can lead to complications that can be mild to severe.
An updated review on nonalcoholic steatohepatitis, epidemiology, pathology, diagnosis, treatment modalities and current clinical trials are reviewed.
New England Journal of Medicine review article from November 2017 entitled "Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis" was extensively cited, please see references on the last slide (DOI: 10.1056/NEJMra1503519).
This is purely for educational purposes; I do not diagnose, treat, or offer patient-specific advice by sharing these slides.
One of the common liver problems, fatty liver is a condition in which the liver cells are accumulated with fats. Though, not life-threatening, in some cases, it can lead to complications that can be mild to severe.
An updated review on nonalcoholic steatohepatitis, epidemiology, pathology, diagnosis, treatment modalities and current clinical trials are reviewed.
New England Journal of Medicine review article from November 2017 entitled "Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis" was extensively cited, please see references on the last slide (DOI: 10.1056/NEJMra1503519).
This is purely for educational purposes; I do not diagnose, treat, or offer patient-specific advice by sharing these slides.
Nonalcoholic Steatohepatitis (NASH) also known as “silent disease” is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are found among all demographics (from children to adults); however, they are more prevalent in younger people. Corner stage of cirrhosis is a form of NASH that can be reversed with proper medication. Moreover, most of the NASH specific pharmaceutical solution are in clinical trial phase
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. The report includes detailed competitive landscape of the global nonalcoholic steatohepatitis market and an analysis of Porter’s five forces model for the NASH market has also been included.
Nonalcoholic Steatohepatitis (NASH) is a type of NAFLD (Nonalcoholic Fatty Liver Disease) which is characterized by inflammation and buildup of excess of fat in the liver. NASH is considered to be strongly associated with insulin resistance, central obesity, reduced glucose tolerance, type II diabetes mellitus (T2DM), arterial hypertension, and hypertriglyceridemia.The exact cause of the NASH has not been illuminated because generally it not same for every patient.
Emergence of noninvasive diagnostic methods for identifying patients (and stratify the NAFLD and NASH populations based on severity and risk of progression) would be a key driver, with significant impact on evolving the market for NASH therapies.
Differences in method of assessment of NASH (Ultrasound, MRI, Liver biopsy, non-invasive tests leads to profound variation in prevalence rates. We estimated that diagnosed NASH prevalence will reach 18 Million by 2027at a compound growth rate of 2.82% for seven major markets i.e. US, EU5 and Japan.
In the United States, we found that NASH Fibrosis (F0) and NASH Fibrosis-1 (F1) accounts for approximately 67% and 13% cases of total NASH respectively.
Obstructive jaundice (OJ) is a common problem in daily clinical practice. However, completely understanding the pathophysiological changes in OJ remains a challenge for planning current and future management. The effects of OJ are widespread, affecting the biliary tree, hepatic cells, liver function, and causing systemic complications. The lack of bile in the intestine, destruction of the intestinal mucosal barrier, and increased absorption of endotoxins can lead to endotoxemia, production of proinflammatory cytokines, and induce systemic inflammatory response syndrome, ultimately leading to multiple organ dysfunction syndrome. Proper management of OJ includes adequate water supply and electrolyte replacement, nutritional support, preventive antibiotics, pain relief, and itching relief. The surgical treatment of OJ depends on the cause, location, and severity of the obstruction. Biliary drainage, surgery, and endoscopic intervention are potential treatment options depending on the patient's condition. In addition to modern medical treatments, Traditional Chinese medicine may offer therapeutic benefits for OJ. A comprehensive search was conducted on PubMed for relevant articles published up to August 1970
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
4. EPIDEMIOLOGY NAFLD is probably most common liver disorder in world incidence of 10–24% in the general population and probably similar figures in Europe and Japan Mostly in 4th to 6th decade of life More common in female Very common in type II DM and Metabolic syndrome 75 % of type II diabetics have some form of NAFLD
5. As far as obesity is regarded, steatosis has been reported in 70% of obese and 35% of lean patients and NASH in 18.5% of obese and 2.7% of lean patients in a consecutive study, although some authors have reported even higher figures (up to 95% in some studies . The prevalence of simple steatosis in obese patients is ∼60%, whereas 20–25% present NASH and 2–3% present cirrhosis .
6. IN INDIA Epidemiological studies suggest prevalence of NAFLD in around 9% to 32% of general population in India with higher prevalence in those with overweight or obesity and those with diabetes or prediabetes Clinicopathological studies show that NAFLD is an important cause of unexplained rise in hepatic transaminases, cryptogenic cirrhosis and cryptogenic hepatocellular carcinoma in Indian patients There is high prevalence of insulin resistance and nearly half of Indian patients with NAFLD have evidence of full-blown metabolic syndrome.
14. PATHOGENESIS Proposed by DAY and JAMES in 1998 Described by “two hit hypothesis” FIRST HIT : disregulation of fatty acid metabolism leads to steatosis SECOND HIT: “oxidative stress” -may be environmental or genetic factors
18. Role of Diet Evidence exists demonstrating that the diet of NASH patients is rich in unsaturated fat and cholesterol but poor in polyunsaturated fat, fiber, and vitamins E and C compared with that of healthy subjects. These levels of unsaturated fat in the diet correlate with a lower sensitivity to insulin, with high postprandial triglyceride levels in these patients, and with other aspects of the metabolic syndrome
19. Role of intestinal bacterial overgrowth in the pathogenesis of NASH A clear link between intestinal bacterial overgrowth and liver damage during NASH has recently been established. Bacterial overgrowth has been detected in NASH patients with breath tests with lactulose and D-xylose , as well as in some forms of secondary NASH, such as that associated with obesity-related intestinal surgery Intestinal bacteria may increase hepatic oxidative stress by at least two mechanisms 1) increased endogenous ethanol production 2) release of LPS.
22. HISTOPATHOGENESIS Features Present in all or most cases : Macrovesicularsteatosis Parenchymal inflammation Hepatocyte necrosis Bollooning degeneration
24. Features Observed with varying frequency : Perivenularperisinusoidal or periportal fibrosis Cirrhosis Mallory bodies Glycogenated nuclei Lipogranulomas and stainable hepatic iron
26. LABORATORY FEATURES COMMON: - 2 to 4 fold elevation serum ALT and AST AST/ALT < 1 in most patients - Serum alkphosphatase level slightly elevated in one third pt. - Normal serum bil and serum albumin & PT - Elevated serum ferritin
28. ultrasonographic fatty liver grades. Grade 0 Normal parenchymal liver ecogenicity Grade 1 Increased liver echogenicity without haziness of vessel walls Grade 2 Increased liver echogenicity with haziness of vessel walls Grade 3 Increased liver echogenicity leading to loss of normal contrast between liver and diaphragm
31. DIAGNOSTIC APPROACH Elevated lever enzyme or Heptomegaly Exclude excessive alcohol and other form of liver disease by history & lab tests Image liver by US , CT or MRI Normal Fatty Liver present Liver Biopsy Consider Liver biopsy to stage dis& define risk of progression
32.
33. histological evaluation of morphological changes in a liver biopsy is required, in particular, to differentiate between simple steatosis and steatohepatitis.
34. The presence of obesity or type 2 diabetes, high levels of alanineaminotransferase (ALT) and triglycerides, hypertension, and an aspartateaminotransferase/ALT ratio greater than unity may justify performing a biopsy
35.
36. POTENTIAL THERAPIES AVOIDANCE OF TOXINS: - Discontinue offending medication/toxins - Minimize alcohol intake EXERCISE AND DIET: -Moderate sustained exercise and weight loss in overweight patients BARIATRIC SURGERY FOR MORBID OBESITY
37. Diet Modification advised to reduce saturated/trans fat and increase polyunsaturated fat, with special emphasize on omega-3 fatty acids. reduce added sugar to its minimum, try to avoid soft drinks containing sugar, including fruit juices that contain a lot of fructose, and increase their fiber intake. For the heavy meat eaters, especially those of red and processed meats, less meat and increased fish intake should be recommended. Minimizing fast food intake will also help maintain a healthy diet.
38. exercise An 8-week resistance exercise programme brought about an approximately 13% reduction in liver fat. This was accompanied by an approximately 12% increase in insulin sensitivity, and increased fat oxidation during submaximal exercise in the absence of any change in body weight. Resistance exercise provides an alternative to aerobic exercise; it improves muscular strength, muscle mass and metabolic control, safely and effectively, in vulnerable populations independent of weight loss. It places less of a demand on the cardiorespiratory system and may therefore be accessible to more patients
39.
40. Correction of obesity with hypocaloric diets and physical exercise Rapid weight loss and long-lasting fasting periods should be avoided, since they lead to an increase in the flow of FFAs to the liver. A gradual weight reduction has been associated with an improvement of hepatic lesions, including fibrosis
41.
42. Control of hyperglycemia with diet, insulin, or oral antidiabetic agents. Simultaneous treatment of overweight in these patients is of paramount importance.
43. Withdrawal from treatment with amiodarone, perhexilinemaleate, tamoxifen, or other drugs to which NASH development has been attributed. Likewise, exposure to hepatotoxic environmental agents, including alcohol, should be avoided, particularly where fibrosis is histologically detected in a biopsy
44. Control of hyperlipemia with diet, or, when indicated, with hypolipemic drugs. Gemfibrozil (600 mg/day) or bezafibrate showed more favorable results in terms of biochemical parameters and development of steatosis. Orlistat, an inhibitor of lipoprotein lipase, has been recently proven to be beneficial for NASH patients, inducing normalization of transaminases and reduction in liver steatosis and inflammatory activity
45. Change in IV Nutrition In parenteral nutrition-associated NASH, modifying the composition of the infusion, replacing glucose with lipids. Glucose stimulates insulin secretion, thus inhibiting FFA oxidation and leading to their accumulation and synthesis in the liver. Supplementation with choline is indicated to increase the synthesis of lecitin, necessary for VLDL formation
46. For those undergoing bariatric surgery In patients undergoing surgery to treat obesity, reconstructing intestinal transit to help improve hepatic lesions. Metronidazol may prevent the development of NASH by preventing the absorption of bacterial overgrowth-derived endotoxin in excluded loops
47. Antibiotics Because bacterial overgrowth–derived lipoproteins may be involved in the development of NASH, oral metronidazol (0.75–2 g/day for 3 months, followed by a similar period without treatment) may be efficacious in reverting steatosis and, in some cases, inflammation and fibrosis. Oral polymixin B may improve parenteral nutrition–associated NASH by reducing liver exposure to intestinal flora-derived endotoxin.
48. Metadoxine has proved efficacious in the treatment of alcoholic liver steatosis, as shown by biochemical data and echographical signs. This drug restores hepatic glutathione concentrations and acts as an antifibrogenic agent. These therapeutic effects, along with the proven efficacy in steatosis, may justify its indication for the treatment of NASH.
49. Silymarin also possesses antioxidant and antifibrogenic properties, with beneficial effects in alcoholic liver disease , supporting its indication for the treatment of NASH. Betaine treatment has shown beneficial biochemical and histological effects in a pilot study of NASH patients . Additional drugs currently in assessment include ghrelin and pentoxyphylline . Other promising, potentially useful antioxidant agents include vitamin E and N-acetylcysteine.
50. Reduction of peripheral resistance to insulin rosiglitazone have also shown some efficacy in improving liver enzyme levels and histology . Similarly, pioglitazone has also been tested in a pilot study with 18 nondiabetic NASH patients . Administration of a daily dose of 30 mg for 48 weeks resulted in normalization of ALT levels in 72% of patients. Hepatic fat content and size, as well as glucose and FFA sensitivity to insulin, were consistently improved, as well as histological signs of steatosis.
51. Metformin In addition to improving hyperinsulinemia and insulin sensitivity in animals and humans , metformin inhibits hepatic TNF-α and several TNF-inducible responses, which, as stated above, are likely to promote hepatic steatosis and necrosis. Metformin statistically significantly improved serum alanine/aspartateaminotransferase levels as well as insulin resistance, whereas it decreased insulin and C-peptide levels. metformin could be a promising agent for the treatment of NASH patients
52. Vitamin E therapy, as compared with placebo, was associated with a significantly higher rate of improvement in nonalcoholicsteatohepatitis (43% vs. 19%, P=0.001),
53. LIVER TRANSPLANTATION Patients with NAFLD in whom end stage liver disease developed should be evaluated Outcome of liver transplantation in these patient is good NAFLD can recur after liver transplantation Risk factors for recurrent NAFLD after liver transplantation are hypertriglyceridemia, DM, obesity & glucocorticoids therapy
54. Take Home Message NAFLD is more common than alcoholic fatty liver disease Insulin resistance and free radical oxidative damage is the culprit for pathogenesis Diagnosis of exclusion Diet Control and exercise is the hope for future Supplement therapies have got some role